-
Scientists studied the molecular evolution of tumors after exposure to genetically damaging chemicals. They discovered that the chemical-induced defects in individual DNA building blocks are not repaired immediately but are passed on over several rounds of cell division.
-
A new project called "DeLiver" is currently developing a transport system for liver transplants. This system ensures optimal monitoring of organ functions with a flexible temperature regulation, nutrition and oxygen supply of the organ.
-
The tissue hormone angiotensin II plays a role in the development of glaucoma. This finding could influence the diagnosis and therapy of glaucoma in the future.
-
Researchers used infrared (IR) microscopes based on quantum cascade lasers (QCLs) to classify tissue samples of colorectal cancer. Using AI, it was possible to differentiate tumor types with great accuracy within 30 minutes allowing for a prognosis of the disease and the therapy choice.
-
The Körber Prize for European Science 2020 will be awarded to Hungarian physician Botond Roska, who has revolutionized ophthalmology and the field of vision and retinal research. He has set himself the goal of restoring sight to the blind.
-
Some elderly and sick patients benefit from a minimally invasive treatment of an aortic aneurysm. However, open aortic artery operations continue to be a good (and in cases the only sensible) alternative.
-
Researchers identified thousands of specific peptides on the surface of cells for the first time. These so-called cryptic peptides mark tumor cells to a significant extent and may provide a new starting point for cancer immunotherapies.
-
Outcomes of the C-OPTIMISE trial showed that a reduced maintenance dose of certolizumab pegol may be used in patients with axial spondyloarthritis (axSpA) treated with the drug for a year and who achieved sustained disease remission, regardless of subpopulation.
-
A concept of the new ‘Composite of Relevant Endpoints for Sjogren’s Syndrome’ (CRESS) has been developed, which enables discriminating between abatacept and placebo response in patients with this condition.
-
Data from the first large, randomized, placebo-controlled trial OA TREAT, focusing on erosive hand osteoarthritis, showed that hydroxychloroquine was no more effective than placebo for changes in pain, function, and radiographic scores in the study period.
-
These recommendations focus on prevention of COVID-19; managing patients in general; and managing patients who have been infected or have been in contact with a COVID-19 patient. They were simultaneously published in the Annals of the Rheumatic Diseases.
-
Main trial data from the head-to-head EXCEED trial showed that, for patients who suffer from psoriatic arthritis and who are biologic-naïve, secukinumab monotherapy does not offer greater musculoskeletal benefits than adalimumab.
-
For the first time, safety and tolerability results were reported for multiple ascending doses of rozibafusp alfa in patients with RA. This showed greater improvement from baseline in Patient Global Assessments and Physician Global Assessments as well as a non-linear, target-mediated disposition.
-
Ankylosing spondylitis patients with longstanding disease achieved significant improvements in both lumbar spine and hip BMD during 8 years of tumor necrosis factor-alpha (TNF-α) blocking therapy- The effect in the lumbar spine was most pronounced and main improvements occurred during the first 4 years of treatment.
-
A first-in-class therapeutic nanoparticle drug has been developed for the specific targeting of anti-citrullinated protein antibodies, which may be a promising agent for targeting antibodies to citrullinated proteins and peptides (ACPAs).
-
In a pre-specified subgroup analysis of the phase3b EXCEED trial, patients with psoriatic arthritis achieved higher responses with secukinumab compared with adalimumab in simultaneous improvement of joint and skin disease and in skin specific endpoints at week 52.
-
The phase 3 CREDO-1 trial showed that treatment with olokizumab over 24-weeks was associated with significant improvements in the signs, symptoms, and physical function of RA. The safety profile of olokizumab was consistent with previous phase 2 trials with this agent.
-
Results from the phase 4 CONTROL trial shows that adding adalimumab to the treatment regimen of methotrexate results in better outcomes than methotrexate dose escalation in patients with psoriatic arthritis who did not respond sufficiently to initial methotrexate therapy.
-
Treatment of rheumatoid arthritis patients with tumour necrosis factor (TNF) inhibitors shows a significantly lower risk of serious venous thromboembolism (VTE) events compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
-
In a phase 3 trial, patients with psoriatic arthritis who have an inadequate response to ≥1 non-bDMARD, showed improvement in musculoskeletal symptoms, psoriasis, physical function, pain, and fatigue and inhibited radiographic progression when treated with upadacitinib.
